XAV-19

N/A

Report date: 2023/01/24 20:00:20

Base Information

Drug NameXAV-19
Drug Alias NameXAV-19
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionSARS-CoV-2 Spike glycoprotein receptor binding domain antagonists
TargetsSARS-CoV-2 Spike glycoprotein receptor binding domain
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaRomaniaTurkey +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesXenothera Sas
China Registration ClassN/A

Develop Information

Active CompaniesXenothera Sas
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A